MedPath

Arterial wall inflammation measured with 18F-FDG PET/CT in patientswith statin intolerance before and after treatment with a PCSK-9 inhibitor

Completed
Conditions
Cardiovascular risk Statin intolerance
Registration Number
NL-OMON20315
Lead Sponsor
niversity of Amsterdam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
50
Inclusion Criteria

Increased CV-risk

Aged 50 years and older

Exclusion Criteria

Major exclusion criteria:

CV-event in last 3 months

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is the change in 18F-FDG target to background ratio (TBR) following 12 weeks of PCSK-9 inhibition
Secondary Outcome Measures
NameTimeMethod
The secondary endpoints are the difference in inflammatory parameters before and<br>after PCSK-9 inhibition and to evaluate whether there is a correlation between 18F-FDG PET<br>activity in arterial wall and circulating inflammatory markers
© Copyright 2025. All Rights Reserved by MedPath